Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elenbecestat - Biogen/Eisai

Next Previous
Drug Profile

Elenbecestat - Biogen/Eisai

Alternative Names: E-2609

Latest Information Update: 03 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Inc
  • Developer Biogen; Eisai Inc; GE Healthcare
  • Class Antidementias; Small molecules
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 27 Jul 2025 Pharmacodynamics data from the phase III MissionAD1 trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2025 (AAIC-2025)
  • 13 Sep 2019 Discontinued - Phase-I for Alzheimer's disease in USA (PO), after September 2019
  • 13 Sep 2019 Discontinued - Phase-III for Alzheimer's disease (Early-stage disease) in China, Taiwan, South Africa, Slovakia, Singapore, Portugal, Mexico, Italy, Hungary, Finland, Denmark, Croatia, Chile, United Kingdom, Poland, South Korea, Greece, Germany, France, Czech Republic, Bulgaria, Canada, Australia, Argentina, Spain, Austria, Japan, USA (PO), after September 2019

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top